# Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence

Study · id `cardio:ct-nct03592823` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03592823](<https://clinicaltrials.gov/study/NCT03592823>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03592823

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT03592823. Randomized; double masking; primary purpose prevention. Start 2018-08-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT03592823, source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)
- Planned start: 2018-08-01 (anticipated) (ClinicalTrials.gov record NCT03592823, source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03592823, source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)
- Completion: 2020-08-01 (anticipated) (ClinicalTrials.gov record NCT03592823, source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03592823, source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03592823-2018-07-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence
- Condition: Atrial Fibrillation
- Intervention (Drug): Hydroxychloroquine Sulfate 200 Mg Tablet
- Lead sponsor: First Affiliated Hospital of Harbin Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Harbin Medical University (`cardio:org-first-affiliated-hospital-of-harbin-medical-university`)

## Provenance

Content hash: f7342b1399810d48025f72e384af5199c3c1e304d517e9c8f0fc8d5f661f709e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
